A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.
However, several targeted therapies have recently been developed for potentially actionable alterations, including BRAF and human epidermal growth factor receptor 2 (HER2) oncogenes, advancing the ...
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.
Morning Overview on MSN
How gene mutations disrupt cell growth and trigger cancer?
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...
Scientists at Duke-NUS Medical School have identified a molecular “switch” that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some ...
The fireside chat session is scheduled for Wednesday, March 11, in Miami, Florida at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results